{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002987","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.121721+00:00","generated_at":"2026-05-22T04:37:00.395875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M","bullets":["Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.","Net loss $10.7M ($0.36/share) vs $6.6M ($0.27/share) a year ago.","Operating expenses $13.0M, up from $8.7M on commercial expansion and R&D.","Cash $46.4M at March 31; 30,053,142 shares outstanding as of May 8.","Urology APC Level 7 codes effective 2025; TULSA-AI BPH module and TULSA+ planned H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002987","json":"https://secwatch.observer/filing/0001171843-25-002987.json","markdown":"https://secwatch.observer/filing/0001171843-25-002987.md","text":"https://secwatch.observer/filing/0001171843-25-002987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/0001171843-25-002987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/f8k_050825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:37:00.395875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}